Protalix BioTherapeutics Inc. reported positive Phase III data for its enzyme replacement therapy Uplyso (taliglucerase alfa), staking its claim as another serious contender in the Gaucher disease space held almost exclusively by Genzyme Corp.'s Cerezyme (imiglucerase). (BioWorld Today)

Two months after a hefty capital raise signaled a prospective shopping spree for Onyx Pharmaceuticals Inc., the Emeryville, Calif.-based firm snatched up Proteolix Inc. in a potential $851 million deal centered on carfilzomib, a proteasome inhibitor poised to take on Velcade (bortezomib) in the multiple myeloma space. (BioWorld Today)